Out to re­vamp plant-based drug man­u­fac­tur­ing, An­theia locks in part­ner­ship with syn­thet­ic bi­ol­o­gy gi­ant Gink­go

With sup­ply chain short­ages at the fore­front of near­ly every busi­ness in the world right now, whether it be chick­en wings or CAR-T cell ther­a­py, syn­thet­ic bi­ol­o­gy up­start An­theia is look­ing to aid in the fight. It just an­nounced a deal with a gi­ant in the field to help it along.

An­theia will join forces with Gink­go Bioworks to beef up its pipeline of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents and key start­ing ma­te­ri­als, lever­ag­ing Gink­go’s high-through­put en­zyme de­sign and screen­ing in­fra­struc­ture to scale up at high­er speed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER